Complement in Tumourigenesis and the Response to Cancer Therapy.
Complement in Tumourigenesis and the Response to Cancer Therapy.
复制标题
DOI：
10.3390/cancers13061209
复制
发表时间：
2021-03-10
期刊：
影响因子：
5.2
通讯作者：
Lynam-Lennon N
中科院分区：
文献类型：
--
作者：
O'Brien RM;Cannon A;Reynolds JV;Lysaght J;Lynam-Lennon N
越来越多的证据支持补充剂在癌症的发展和对癌症治疗的反应中发挥作用。肿瘤微环境中补体表达失调与抗肿瘤免疫的抑制和不良临床结局有关。已证明补体信号改变免疫环境，促进增殖和促进转移。靶向补体信号传导与目前的治疗方法相结合，可能有可能实现对肿瘤生长的更好控制。近年来，我们对先天免疫以外的补体系统的认识取得了显着进展。现代的理解是，补体系统在恶性肿瘤中具有多方面的作用，影响癌发生、转移表型的获得和对治疗的反应。局部免疫细胞产生和响应补体成分的能力为它们的调节以及随后的肿瘤微环境重塑提供了有价值的见解。这些新发现推进了我们对支持肿瘤生长的免疫抑制机制的理解，并揭示了潜在的治疗靶点。这篇综述讨论了目前对补体在癌症中的认识，概述了直接和免疫细胞介导的作用。还介绍了补体在响应诸如化学疗法、放射疗法和免疫疗法的疗法中的作用。虽然补体活性在很大程度上是背景和癌症类型依赖性的，但显然已经确定了有希望的治疗途径，特别是在联合治疗中。
Increasing evidence supports a role for complement in the development of cancer and the response to cancer treatments. Dysregulated complement expression within the tumour microenvironment has been linked to the suppression of anti-tumour immunity and poor clinical outcomes. Complement signals have been demonstrated to alter the immune milieu, promote proliferation and facilitate metastasis. Targeting complement signalling in combination with current treatments may have the potential to achieve improved control of tumour growth. In recent years, our knowledge of the complement system beyond innate immunity has progressed significantly. A modern understanding is that the complement system has a multifaceted role in malignancy, impacting carcinogenesis, the acquisition of a metastatic phenotype and response to therapies. The ability of local immune cells to produce and respond to complement components has provided valuable insights into their regulation, and the subsequent remodeling of the tumour microenvironment. These novel discoveries have advanced our understanding of the immunosuppressive mechanisms supporting tumour growth and uncovered potential therapeutic targets. This review discusses the current understanding of complement in cancer, outlining both direct and immune cell-mediated roles. The role of complement in response to therapies such as chemotherapy, radiation and immunotherapy is also presented. While complement activities are largely context and cancer type-dependent, it is evident that promising therapeutic avenues have been identified, in particular in combination therapies.
登录
查看更多内容
影响因子：
3.6
作者：
Baskar R;Lee KA;Yeo R;Yeoh KW
通讯作者：
Yeoh KW
影响因子：
7.3
作者：
Barros FM;Carneiro F;Machado JC;Melo SA
通讯作者：
Melo SA
影响因子：
4.4
作者：
Ajona, Daniel;Hsu, Yi-Fan;Pio, Ruben
通讯作者：
Pio, Ruben
影响因子：
8
作者：
Block, Ines;Mueller, Carolin;Mollenhauer, Jan
通讯作者：
Mollenhauer, Jan
T 辅助细胞 1 免疫需要 CD4⁺ T 细胞中补体驱动的 NLRP3 炎性体活性。
DOI：
10.1126/science.aad1210
发表时间：
2016-06-17
期刊：
Science (New York, N.Y.)
影响因子：
--
作者：
Arbore G;West EE;Spolski R;Robertson AAB;Klos A;Rheinheimer C;Dutow P;Woodruff TM;Yu ZX;O'Neill LA;Coll RC;Sher A;Leonard WJ;Köhl J;Monk P;Cooper MA;Arno M;Afzali B;Lachmann HJ;Cope AP;Mayer-Barber KD;Kemper C
通讯作者：
Kemper C